Global pharmaceutical pricing strategies: profit implications of price discounting
by Christopher J. Longo
International Journal of Economics and Business Research (IJEBR), Vol. 2, No. 6, 2010

Abstract: Global pharmaceutical pricing strategies have been debated in published literature; however, these debates have not accounted for the differences in elasticity of demand between the public, private and cash paying markets. A mathematical model is presented that explores several plausible scenarios for global pharmaceutical profit by highlighting the differences between regulated (highest percentage public financing) vs. unregulated (highest percentage private financing) marketplaces. The model identifies different short-run demand dynamics based on the mix of public, private and cash paying purchases using an example of a new entry by a single firm in an established therapeutic area. Analyses suggest that when the price elasticity of demand exceeds −0.21 (published range: −0.12 to −0.80), while holding other variables within plausible ranges, a 10% price decrease results in a net increase in global profit under several scenarios. The model suggests that under certain conditions it may prove advantageous for a pharmaceutical company to consider global price discounting.

Online publication date: Sun, 03-Oct-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Economics and Business Research (IJEBR):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com